Related Experiment Video
Updated: Aug 16, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
The design, patient population and outcomes from the Bypass Angioplasty Revascularization Investigation (BARI)
1The Epidemiology Data Center, University of Pittsburgh, PA 15261, USA.
Insights
Coronary artery bypass grafting (CABG) significantly improved 7-year survival in diabetic patients compared to percutaneous transluminal coronary angioplasty (PTCA). No survival difference was found between CABG and PTCA in non-diabetic patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Symptomatic multivessel coronary artery disease requires effective revascularization strategies.
- Coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA) are primary treatment options.
- The Bypass Angioplasty Revascularization Investigation (BARI) aimed to compare these interventions.
Purpose of the Study:
- To compare the long-term efficacy of CABG versus PTCA in patients with multivessel coronary artery disease.
- To specifically evaluate treatment outcomes based on diabetic status.
Main Methods:
- A randomized trial comparing CABG and PTCA.
- Follow-up of 7-year survival and clinical events.
- Subgroup analysis of patients with and without diabetes mellitus.
Main Results:
- Overall 7-year survival favoured CABG.
- In patients with diabetes mellitus, CABG showed an overwhelming survival benefit (23.6% vs 44.3% mortality, p=0.0011).
- No significant difference in survival was observed for non-diabetic patients (13.6% vs 13.2%, p=0.72).
- PTCA patients had fewer in-hospital Q-wave MIs but more repeat revascularizations and angina.
Conclusions:
- CABG offers a significant survival advantage over PTCA for diabetic patients with multivessel coronary artery disease.
- Treatment choice between CABG and PTCA should consider diabetic status.
- Further research may explore mechanisms behind the differential treatment effect.
Abstract:
The Bypass Angioplasty Revascularization Investigation (BARI) was designed to compare CAGB and PTCA for patients with symptomatic multivessel coronary artery disease. The randomized trial reported significant differences in 7-year survival favouring CABG. However, for the 353 patients with treated diabetes mellitus, an overwhelming benefit associated with CABG was seen (mortality: 23.6% CABG vs 44. 3% PTCA, p=0.0011), whilst no treatment difference was observed for the 1476 non-diabetic patients (13.6% CABG vs 13.2% PTCA, p=0.72). Patients assigned to PTCA experienced fewer in-hospital Q-wave MIs, but these patients received more revascularization procedures and more often had angina during follow-up.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management